459 related articles for article (PubMed ID: 28019684)
1. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
Trejo P; Fassier F; Glorieux FH; Rauch F
J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating?
Vasanwala RF; Sanghrajka A; Bishop NJ; Högler W
J Bone Miner Res; 2016 Jul; 31(7):1449-54. PubMed ID: 26845496
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
4. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series.
Andersen JD; Bünger MH; Rahbek O; Hald JD; Harsløf T; Langdahl BL
Osteoporos Int; 2019 Feb; 30(2):513-517. PubMed ID: 30448959
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O
J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993
[TBL] [Abstract][Full Text] [Related]
6. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
7. Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation.
van de Laarschot DM; Zillikens MC
Bone; 2016 Oct; 91():148-51. PubMed ID: 27477003
[TBL] [Abstract][Full Text] [Related]
8. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
11. Mid-term Results of Femoral and Tibial Osteotomies and Fassier-Duval Nailing in Children With Osteogenesis Imperfecta.
Azzam KA; Rush ET; Burke BR; Nabower AM; Esposito PW
J Pediatr Orthop; 2018 Jul; 38(6):331-336. PubMed ID: 27379783
[TBL] [Abstract][Full Text] [Related]
12. Unusual Femur Stress Fractures in Children With Osteogenesis Imperfecta and Intramedullary Rods on Long-term Intravenous Pamidronate Therapy.
Hegazy A; Kenawey M; Sochett E; Tile L; Cheung AM; Howard AW
J Pediatr Orthop; 2016; 36(7):757-61. PubMed ID: 26090982
[TBL] [Abstract][Full Text] [Related]
13. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
Landsmeer-Beker EA; Massa GG; Maaswinkel-Mooy PD; van de Kamp JJ; Papapoulos SE
Eur J Pediatr; 1997 Oct; 156(10):792-4. PubMed ID: 9365071
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
15. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
Munns CF; Rauch F; Zeitlin L; Fassier F; Glorieux FH
J Bone Miner Res; 2004 Nov; 19(11):1779-86. PubMed ID: 15476577
[TBL] [Abstract][Full Text] [Related]
16. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.
Vuorimies I; Arponen H; Valta H; Tiesalo O; Ekholm M; Ranta H; Evälahti M; Mäkitie O; Waltimo-Sirén J
Bone; 2017 Jan; 94():29-33. PubMed ID: 27725317
[TBL] [Abstract][Full Text] [Related]
17. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
18. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
Trejo P; Rauch F
Osteoporos Int; 2016 Dec; 27(12):3427-3437. PubMed ID: 27492436
[TBL] [Abstract][Full Text] [Related]
19. Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma.
Chen Y; Sebag M; Powell TI; Morin SN
J Musculoskelet Neuronal Interact; 2018 Sep; 18(3):375-381. PubMed ID: 30179215
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative bleeding in patients with osteogenesis imperfecta type III treated by Fassier-Duval femoral rodding: analysis of risk factors.
Persiani P; Pesce MV; Martini L; Ranaldi FM; D'Eufemia P; Zambrano A; Celli M; Villani C
J Pediatr Orthop B; 2018 Jul; 27(4):338-343. PubMed ID: 28723699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
